IP Library Patent Application 12748075
Patent Application
App. No. 12/748,075

RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/748,075
Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, cosmetic, cosmeceutical, prophylactic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of disease (e.g., cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases), condition, trait (e.g., hair growth and removal), genotype and phenotype that responds to modulation of gene expression or activity in a cell, tissue, or organism. Such small nucleic acid molecules can be administered systemically, locally, or topically.

Claims (12)

1 - 20 . (canceled)

21 . A chemically modified short interfering nucleic acid (siNA) molecule that inhibits expression of a target RNA, wherein:

a) the siNA comprises a sense strand and an antisense strand;

b) each strand is independently 18 to 24 nucleotides in length, and together comprise a duplex having between 17 and 23 base pairs;

c) the antisense strand is complementary to the target RNA sequence;

d) the sense strand has a cap at both 5′- and 3′-ends of the sense strand; and

e) pyrimidine nucleotides in the sense strand are pyrimidine ribonucleotides and purine nucleotides in the sense strand are 2′-O-methyl purine nucleotides.

22 . The siNA molecule of claim 21 , comprising a 3′-overhang on one or both strands.

23 . The siNA molecule of claim 21 , wherein pyrimidine nucleotides in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and purine nucleotides present in the antisense strand are 2′-O-methyl purine nucleotides.

24 . The siNA molecule of claim 23 , wherein the antisense strand has a phosphorothioate internucleotide linkage at the 3′end.

25 . The siNA molecule of claim 23 , comprising three ribonucleotides at the 5′-terminus of the antisense strand.

26 . A composition comprising the siNA molecule of claim 21 and a pharmaceutically acceptable carrier or diluent.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2010
From: BEIGELMAN, LEONID; MCSWIGGEN, JAMES
To: MERCK SHARP & DOHME CORP.
Reel/Frame 024482/0050 →